Hetero Drugs

Hetero Drugs Limited
TypePrivate
IndustryPharmaceuticals
Founded1993
FounderDr BPS Reddy
HeadquartersHyderabad, India
Key people
Dr Vamsi Reddy
Number of employees
Over 22,000
Websitewww.heteroworld.com

Hetero Drugs is an Indian pharmaceutical company and the world’s largest producer of anti-retroviral drugs. Hetero’s business includes APIs, generics, biosimilars, custom pharmaceutical services, and branded generics.

Operations

Hetero group employs over 21,000 people. Hetero is a player in the active pharmaceutical ingredients market and finished dosages.[1] It has marketing presence in over 127 countries.

Hetero has supplied antiretroviral drugs to patients across more than 100 countries globally.[2]

Today, Oseltamivir, sold under its brand name Fluvir, is also indicated for A[H1N1] virus, also known as swine flu.

Hetero also produces hepatitis C antivirals such as Sofovir (sofosbuvir) and Ledifos (a fixed-dose combination of sofosbuvir and ledipasvir).

Company structure

Hetero Group's subsidiaries include Hetero Drugs, Hetero Labs, Hetero Research Foundation, Genx Laboratories and also foreign subsidiaries such as Camber Pharma Inc. in United States, Hetero Europe in Europe, and Richmond Labs in Argentina. The group is also investing in the wind power industry with a goal to reach 1000 megawatts by 2017.[3]

2009 Swine flu outbreak

In 2009, as the swine flu outbreak was spreading across the globe and various health organizations and government agencies were piling up stocks of Oseltamivir as precautionary measures, Hetero supplied generic Oseltamivir under its brand name Fluvir.[4]

Hetero delivered 10 million doses of Oseltamivir to the Indian government in 2009,[5] and shipped about 80 million doses to over 60 countries.[6] Hetero received its second order from Indian government to supply another 10 million doses of Oseltamivir later in 2009.[7]

COVID-19 experimental drugs

The company has launched the generic version of experimental COVID-19 drug Remdesivir under brand name Covifor after acquiring license from Gilead Sciences and obtaining approval from CDSCO, the Indian drug control authority.[8] On July 29, 2020 the company launched its version of the anti viral drug Favipiravir under the brand name Favivir, after getting approval from Drugs Controller General of India (DCGI), used in the treatment of mild to moderate COVID-19 patients.[9] On November 27, 2020, Hetero Labs signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture 100 million doses of the Sputnik V vaccine.[10]

References

  1. ↑ "Archived copy". Archived from the original on 16 September 2016. Retrieved 11 July 2016.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ↑ ":: Welcome to Hetero ::". Heterodrugs.com. Archived from the original on 17 January 2014. Retrieved 11 January 2014.
  3. ↑ "Hetero Windpower". Hetero. Retrieved 22 June 2018.
  4. ↑ Swine flu: Centre taps Hetero for generic Tamiflu supplyArchived 30 April 2009 at the Wayback Machine
  5. ↑ Khomba Singh, ET Bureau 5 May 2009, 12.03am IST (5 May 2009). "Hetero bags mega chunk of govt's anti-flu drug deal - Economic Times". Economictimes.indiatimes.com. Retrieved 11 January 2014.{{cite web}}: CS1 maint: multiple names: authors list (link)
  6. ↑ "Hyderabad pharma cos cash in on Swine-Flu fever". Moneycontrol.com. Retrieved 11 January 2014.
  7. ↑ Khomba Singh, ET Bureau 22 August 2009, 03.02am IST (22 August 2009). "Hetero bags deal for 10 m Tamiflu - Economic Times". Economictimes.indiatimes.com. Retrieved 11 January 2014.{{cite web}}: CS1 maint: multiple names: authors list (link)
  8. ↑ "Covid-19: Hyderabad-based Hetero Labs Ltd prices generic version of remdesivir at Rs 5,400 per vial". The Indian Express. 25 June 2020.
  9. ↑ Kumar, N. Ravi (29 July 2020). "India's Hetero Labs wins approval to sell COVID-19 drug favipiravir". The Hindu. ISSN 0971-751X. Retrieved 9 September 2020.
  10. ↑ Das, Sohini (27 November 2020). "Hetero Labs to manufacture 100 mn doses of Sputnik V vaccine for India". Business Standard India. Retrieved 28 November 2020.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.